Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 3/2014

01-09-2014 | short review

Colorectal cancer: screening and some notes on the prevention

Authors: Paul Bergmeister, MD, Alois Hermann Lang, MD

Published in: memo - Magazine of European Medical Oncology | Issue 3/2014

Login to get access

Abstract

At the moment cancer screening is a hot topic which is widely discussed in scientific as well as in popular press. The expected benefits, improvement of prognosis and the reduction of mortality, must be weighed against potential harms, such as the risk of over-diagnosis, false-positive findings, and complications of invasive screening examinations. Screening for breast, cervical, and colorectal cancer has proven to be effective and is therefore recommended by major medical societies and international guidelines. Different tests for colorectal cancer screening are available. Besides established strategies using fecal occult blood test and colonoscopy new and potentially less invasive techniques are on the rise. Our aim is to discuss different strategies for colorectal cancer screening and to present the available screening tests. According to the World Health Organization prevention is the most cost-effective long-term strategy for the fight against cancer. Almost half of all cancer deaths are related to preventable causes. In general, life style modification and some dietary advices can be recommended, but the role of micronutrient supplements remains unclear. There is mounting evidence that some drugs such as nonsteroidal anti-inflammatory drugs, statins, or metformin may have a chemoprotective effect, but is there enough evidence to give general recommendations?
Literature
1.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.PubMedCrossRef
2.
Bundesanstalt Statistik Österreich. Statistik Austria: Dickdarm, Enddarm. Online 2013.
3.
Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JMA, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375:1624–33.PubMedCrossRef
4.
Kinzler KW, Vogelstein B. The genetic basis of human cancer. 2nd ed. McGraw-Hill Professional; 2002. pp. 583–612.
5.
6.
Gondos A, Bray F, Brewster DH, Coebergh JWW, Hakulinen T, Janssen-Heijnen MLG, et al. Recent trends in cancer survival across Europe between 2000 and 2004: a model-based period analysis from 12 cancer registries. Eur J Cancer. 2008;44:1463–75.PubMedCrossRef
7.
Lieberman DA. Clinical practice. Screening for colorectal cancer. N Engl J Med. 2009;361:1179–87.PubMedCrossRef
8.
Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99:1462–70.PubMedCrossRef
9.
Moayyedi P, Achkar E. Does fecal occult blood testing really reduce mortality? A reanalysis of systematic review data. Am J Gastroenterol. 2006;101:380–4.PubMedCrossRef
10.
Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer. 2013;49:3049–54.PubMedCrossRef
11.
Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JCIY, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010;59:62–8.PubMedCrossRef
12.
Duffy MJ, van Rossum LGM, van Turenhout ST, Malminiemi O, Sturgeon C, Lamerz R, et al. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer. 2011;128:3–11.PubMedCrossRef
13.
Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366:697–706.PubMedCrossRef
14.
Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst. 2003;95:230–6.PubMedCrossRef
15.
Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130–60.PubMedCrossRef
16.
Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial–SCORE. J Natl Cancer Inst. 2011;103:1310–22.PubMedCrossRef
17.
Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Savarino JE, van Ballegooijen M, Kuntz KM, et al. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst. 2010;102:1238–52.PubMedCrossRefPubMedCentral
18.
Minamimoto R, Senda M, Jinnouchi S, Terauchi T, Yoshida T, Inoue T. Detection of colorectal cancer and adenomas by FDG-PET cancer screening program: results based on a nationwide Japanese survey. Ann Nucl Med. 2014;28:212–9.PubMedCrossRef
19.
Negreanu L, Babiuc R, Bengus A, Sadagurschi R. PillCam Colon 2 capsule in patients unable or unwilling to undergo colonoscopy. World J Gastrointest Endosc. 2013;5:559–67.PubMedPubMedCentral
20.
Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–25.PubMedPubMedCentral
21.
Tóth K, Sipos F, Kalmár A, Patai A V, Wichmann B, Stoehr R, et al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS ONE. 2012;7:e46000.PubMedCrossRefPubMedCentral
22.
Pox CP, Schmiegel W. [German S3-guideline colorectal carcinoma]. Dtsch Med Wochenschr. 2013;138:2545.PubMedCrossRef
23.
24.
O’Morain C, Trinity CD, Lambert R. EU Guidelines for quality assurance in CRC screening and diagnosis. (International A for R on C, Rey J-F Institut AT). European Comission; 2010.
25.
Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJW, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5):666–89.PubMedCrossRef
26.
Burn J, Gerdes A-M, Macrae F, Mecklin J-P, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378:2081–7.PubMedCrossRefPubMedCentral
27.
Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila). 2012;5:164–78.PubMedCrossRefPubMedCentral
28.
Nan H, Morikawa T, Suuriniemi M, Imamura Y, Werner L, Kuchiba A, et al. Aspirin Use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst. 2013;105:1852–61.PubMedCrossRef
29.
Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila). 2011;4:655–65.PubMedCrossRefPubMedCentral
30.
Ishikawa H, Wakabayashi K, Suzuki S, Mutoh M, Hirata K, Nakamura T, et al. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med. 2013;2:50–6.PubMedCrossRefPubMedCentral
31.
Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. Gut. 2010;59:1572–85.PubMedCrossRef
32.
33.
Tseng C-H. Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. Eur J Endocrinol. 2012;167:409–16.PubMedCrossRef
34.
Thosani N, Thosani SN, Kumar S, Nugent Z, Jimenez C, Singh H, et al. Reduced risk of colorectal cancer with use of oral bisphosphonates: a systematic review and meta-analysis. J Clin Oncol. 2013;31:623–30.PubMedCrossRef
35.
Higurashi T, Takahashi H, Endo H, Hosono K, Yamada E, Ohkubo H, et al. Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer. 2012;12:118.PubMedCrossRefPubMedCentral
Metadata
Title
Colorectal cancer: screening and some notes on the prevention
Authors
Paul Bergmeister, MD
Alois Hermann Lang, MD
Publication date
01-09-2014
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 3/2014
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0154-8

Other articles of this Issue 3/2014

memo - Magazine of European Medical Oncology 3/2014 Go to the issue

review

Importance of intraoperative radiation therapy in the treatment of soft tissue sarcoma: data at hand

short review

Molecular monitoring of minimal residual disease in acute leukemia

original report

Clinicopathological profile of bilateral breast cancer at a tertiary cancer center in South India

special report

Long-term tolerability of the BRAF inhibitor vemurafenib in patients with metastatic melanoma: current study data and real-life observations

short review

Neoadjuvant chemotherapy for soft tissue sarcoma

short review

Aggressive lymphoma at ASH 2013: R-CHOP under attack?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits